There may be a new obesity drug inarmacies, one that doesn't involve needles or shots. A new latestage clinical study showed Eli Liy's experimental pill cut weight by 11% in patients. But investors aren't cheering.In fact, shares fell on the news. Why. Wall Street was expecting the drug called Orphon to perform better and more in line with its injectable counterparts.For example, Novo Nordisk's blockbuster weight loss shot, WGOI, helped patients shed up to 15% of their body weight in trials. Lily's own shot ...

news uh that we've I guess been waiting for from Eli Liy. Got a look at the stock. Uh although we'll show you that Angelica Peeles that's here and joins us now, but uh as you're talking, we should take a quick look at the uh early morning action in the shares.But take it away. >> Yeah, that early morning action not good. The stock down about 6% right now and that's after we got this highly anticipated data on its obesity pill and clearly there's some disappointment.So let's go through the numbers. people lo ...

Uh we're starting with news that just crossed a few moments ago. Novo Nordis expanding legal action to protect patents from unsafe non-FDA approved semiglutide. And joining us now is CNBC health and pharmaceuticals reporter Angelica Peebles and CNBC's Brandon Gomez.Uh let's start right here. And Brandon, I'm going to kick this off with you. You're on set with me because we did see him and hers.They reported earnings after the bell last night. It was ugly. They clawed back to the flatline and now they're dow ...